Question explored with the scientific record
Conversation so far
- 1 Does ivermectin appear to have a meaningful effect against cancers
- 2 Does ivermectin appear to have a meaningful effect against cancers
Answered on this page ↓
Does ivermectin appear to have a meaningful effect against cancers
The short version: the lab signal is real and reproducible across cell types. The human evidence is still missing, and the doses used in the lab are far above what a pill achieves in blood.
The follow-up asks whether the effect is meaningful, so the honest answer is: meaningful in a dish, unproven in a person. Ivermectin blocks WNT signaling in colon, glioblastoma, and melanoma cells at concentrations around 1 to 2.6 µM [2], and kills over 90 in 100 breast cancer cells at 32 µM within 4 hours [3]. In ovarian cancer lines the killing dose is higher, 12 to 16 µM [5]. In rats with implanted glioma, plain ivermectin did not shrink tumors at all, while an intranasal nanoparticle formulation cut tumor volume by about 70 percent [6]. That last result is the most interesting and the most fragile: it required a delivery system, not a pill.
| Model | Dose | Result |
|---|---|---|
| Colon, glioblastoma, melanoma cells | 1.0 to 2.6 µM | WNT pathway blocked [2] |
| Breast cancer cells | 32 µM, 4 hours | Over 90 in 100 dead [3] |
| Ovarian cancer cells | 12 to 16 µM | Half-maximal killing [5] |
| Rat glioma, plain ivermectin | 60 µg/rat/day | No significant tumor reduction [6] |
| Rat glioma, nanoparticle ivermectin | 60 µg/rat/day | About 70 percent smaller [6] |
The gap between those numbers and a human dose is the whole problem. A standard antiparasitic dose produces blood levels well below the 12 to 32 µM needed to kill cells in a dish, and no record here shows a human trial in cancer patients measuring survival or tumor shrinkage. The Ecuador study found 19 percent of cancer patients self-medicating with ivermectin, with no evidence of benefit reported [1]. The other records are about parasites, COVID, or drug formulation, not cancer outcomes [4][7][8].
My call: the lab mechanism is real and worth pursuing in proper trials, but there is no human evidence that ivermectin treats cancer, and the doses that kill cells in a dish are not reachable with a pill. Confidence: moderate that the lab signal is real, high that human benefit is unproven.
Sources used 8
-
Outcome of Ivermectin in Cancer Treatment: An Experience in Loja-Ecuador
This study investigates the use of ivermectin as an alternative treatment for cancer in rural areas of Loja, Ecuador, revealing that a significant percentage of cancer patients self-medicate with this antiparasitic drug despite a lack of scientific endorsement for its efficacy i…
DOI: 10.3390/nursrep13010030 -
The river blindness drug I vermectin and related macrocyclic lactones inhibit WNT ‐ TCF pathway responses in human cancer
This study identifies Ivermectin and related macrocyclic lactones as effective inhibitors of the WNT-TCF signaling pathway in human cancer cells, suggesting their potential therapeutic use against various cancers.
DOI: 10.15252/emmm.201404084 -
Modulation of P2X4/P2X7/Pannexin-1 sensitivity to extracellular ATP via Ivermectin induces a non-apoptotic and inflammatory form of cancer cell death
Augmenting extracellular ATP signaling through P2X4/P2X7/Pannexin-1 with Ivermectin drives a rapid, inflammatory cancer cell death in breast cancer cells, combining necrotic/pyroptotic and apoptotic pathways via ROS/CaMKII/MPTP and autophagy, with immunogenic-cell-death hallmark…
DOI: 10.1038/srep16222 -
A Case Report of Disseminated Strongyloidiasis Following Chemoradiotherapy for Lung Cancer in a Patient Living in a Non-endemic Area in Japan
This case report documents HTLV-1-associated disseminated Strongyloides stercoralis infection developing after chemoradiotherapy for lung cancer in a non-endemic area of Japan, successfully treated with daily ivermectin followed by six months of intermittent dosing, highlighting…
DOI: 10.2169/internalmedicine.5829-25 -
Ivermectin Augments the Anti-Cancer Activity of Pitavastatin in Ovarian Cancer Cells
This study investigates the synergistic effects of ivermectin and pitavastatin on ovarian cancer cell lines, demonstrating that their combination enhances anti-cancer activity and may reduce the required dosage of pitavastatin.
DOI: 10.3390/diseases11010049 -
Intranasal Delivery of Ivermectin Nanosystems as an Antitumor Agent: Focusing on Glioma Suppression
This study demonstrates nose-to-brain delivery of ivermectin nanocarriers (polymeric nanocapsules and mesoporous silica particles) to suppress glioma growth in a rat model, with intranasal polymeric nanocapsules significantly reducing tumor size and improving histology at a clin…
DOI: 10.1021/acsbiomaterials.5c00642 -
Quantitative proteomics reveals a broad‐spectrum antiviral property of ivermectin, benefiting for COVID‐19 treatment
Using SILAC quantitative proteomics in TOV-21G ovarian cancer cells, this study identified 4447 ivermectin-related proteins, including 52 SARS-CoV-2-related proteins, and enrichment of four antiviral pathways, suggesting ivermectin may have broad-spectrum antiviral activity.
DOI: 10.1002/jcp.30055 -
Co-Processed Crystalline Solids of Ivermectin with Span® 60 as Solubility Enhancers of Ivermectin in Natural Oils
Co-processing ivermectin with Span® 60 via liquid-assisted grinding produced solids that improved ivermectin oil solubility by 66% in avocado oil and 169% in evening primrose oil versus raw material.
DOI: 10.1208/s12249-024-02783-0